Transgenic insulin-like growth factor-1 stimulates activation of COX-2 signaling in mammary glands

Molecular Carcinogenesis

Volumn 51, Issue 12, 2012, Pages 973-983

  Tian, Jie ^a   Lambertz, Isabel ^a   Berton, Thomas R ^a   Rundhaug, Joyce E ^a   Kiguchi, Kaoru ^a,b   Shirley, Stephanie H ^a   Digiovanni, John ^a   Conti, Claudio J ^a   Fischer, Susan M ^a   Fuchs Young, Robin ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

COX 2; IGF 1; Mammary cancer; Stroma; Transgenic mouse

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; DIMETHYLBENZ[A]ANTHRACENE; G PROTEIN COUPLED RECEPTOR; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E2; SOMATOMEDIN C; VASCULOTROPIN;

ADULTHOOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CARCINOGENESIS; BREAST TUMOR; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOFLUORESCENCE TEST; MAMMARY GLAND; MAST CELL; MOUSE; NONHUMAN; PHENOTYPE; PREPUBERTY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; TUMOR MODEL; TUMOR VASCULARIZATION; UPREGULATION; WESTERN BLOTTING; WILD TYPE;

ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; INSULIN-LIKE GROWTH FACTOR I; MAMMARY GLANDS, ANIMAL; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PYRAZOLES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, PROSTAGLANDIN E; SIGNAL TRANSDUCTION; SULFONAMIDES;

MUS MUSCULUS;

EID: 84867745068     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20868     Document Type: Article

References (57)

1. Ruan W, Kleinberg DL. Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocrinology 1999; 140: 5075-5081.
2. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351: 1393-1396.
3. Lann D, LeRoith D. The role of endocrine insulin-like growth factor-I and insulin in breast cancer. J Mammary Gland Biol Neoplasia 2008; 13: 371-379.
4. Yee D. The insulin-like growth factors and breast cancer-Revisited. Breast Cancer Res Treat 1998; 47: 197-199.
5. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472-1489.
6. Kleinberg DL, Wood TL, Furth PA, Lee AV. Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev 2009; 30: 51-74.
7. de Ostrovich KK, Lambertz I, Colby JK, et al. Paracrine overexpression of insulin-like growth factor-1 enhances mammary tumorigenesis in vivo. Am J Pathol 2008; 173: 824-834.
8. Hadsell DL, Greenberg NM, Fligger JM, Baumrucker CR, Rosen JM. Targeted expression of des(1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology 1996; 137: 321-330.
9. Weber MS, Boyle PL, Corl BA, Wong EA, Gwazdauskas FC, Akers RM. Expression of ovine insulin-like growth factor-1 (IGF-1) stimulates alveolar bud development in mammary glands of transgenic mice. Endocrine 1998; 8: 251-259.
10. Tian J, Berton TR, Shirley SH, et al. Developmental stage determines estrogen receptor alpha expression and nongenomic actions that control IGF-1 signaling and mammary proliferation in mice. In revision.
11. DiGiovanni J, Bol DK, Wilker E, et al. Constitutive expression of insulin-like growth factor-1 in epidermal basal cells of transgenic mice leads to spontaneous tumor promotion [In Process Citation]. Cancer Res 2000; 60: 1561-1570.
12. Bol DK, Kiguchi K, Gimenez-Conti I, Rupp T, DiGiovanni J. Overexpression of insulin-like growth factor-1 induces hyperplasia, dermal abnormalities, and spontaneous tumor formation in transgenic mice. Oncogene 1997; 14: 1725-1734.
13. Slaga TJ. Cellular and molecular mechanisms involved in multistage skin carcinogenesis. Carcinog Compr Surv 1989; 11: 1-18.
14. Xu R, Boudreau A, Bissell MJ. Tissue architecture and function: Dynamic reciprocity via extra- and intra-cellular matrices. Cancer Metastasis Rev 2009; 28: 167-176.
15. Mantovani A, Marchesi F, Porta C, Sica A, Allavena P. Inflammation and cancer: Breast cancer as a prototype. Breast 2007; 16: S27-S33.
16. FitzGerald GA. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003; 2: 879-890.
17. Hu M, Peluffo G, Chen H, Gelman R, Schnitt S, Polyak K. Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Natl Acad Sci USA 2009; 106: 3372-3377.
18. Chang SH, Liu CH, Conway R, et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 2004; 101: 591-596.
19. Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001; 276: 18563-18569.
20. Greenhough A, Smartt HJ, Moore AE, et al. The COX-2/PGE2 pathway: Key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009; 30: 377-386.
21. Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ. Cyclooxygenase-2: A target for the prevention and treatment of breast cancer. Endocr Relat Cancer 2001; 8: 97-114.
22. Stoeltzing O, Liu W, Fan F, et al. Regulation of cyclooxygenase-2 (COX-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-I receptor (IGF-IR) system. Cancer Lett 2007; 258: 291-300.
23. Cao Z, Liu LZ, Dixon DA, Zheng JZ, Chandran B, Jiang BH. Insulin-like growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells. Cell Signal 2007; 19: 1542-1553.
24. Nguyen T, Chai J, Li A, Akahoshi T, Tanigawa T, Tarnawski AS. Novel roles of local insulin-like growth factor-1 activation in gastric ulcer healing: Promotes actin polymerization, cell proliferation, re-epithelialization, and induces cyclooxygenase-2 in a phosphatidylinositol 3-kinase-dependent manner. Am J Pathol 2007; 170: 1219-1228.
25. Shirley SH, Rundhaug JE, Tian J, et al. Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells. Cancer Res 2009; 69: 3405-3414.
26. Fischer SM, Lo HH, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999; 25: 231-240.
27. Sung YM, He G, Fischer SM. Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. Cancer Res 2005; 65: 9304-9311.
28. Howe LR. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res 2007; 9: 210.
29. Dempke W, Rie C, Grothey A, Schmoll HJ. Cyclooxygenase-2: A novel target for cancer chemotherapy? J Cancer Res Clin Oncol 2001; 127: 411-417.
30. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: Structures, properties, and functions. Physiol Rev 1999; 79: 1193-1226.
31. Fulton AM, Ma X, Kundu N. Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res 2006; 66: 9794-9797.
32. Ogawa Y, Suzuki T, Oikawa A, et al. Bone marrow-derived EP3-expressing stromal cells enhance tumor-associated angiogenesis and tumor growth. Biochem Biophys Res Commun 2009; 382: 720-725.
33. Amano H, Hayashi I, Endo H, et al. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 2003; 197: 221-232.
34. Kamoshita E, Ikeda Y, Fujita M, et al. Recruitment of a prostaglandin E receptor subtype, EP3-expressing bone marrow cells is crucial in wound-induced angiogenesis. Am J Pathol 2006; 169: 1458-1472.
35. Colby JK, Klein RD, McArthur MJ, et al. Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia 2008; 10: 782-796.
36. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000; 30: 3-21.
37. Liu W, Reinmuth N, Stoeltzing O, et al. Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Cancer Res 2003; 63: 3632-3636.
38. Wu G, Mannam AP, Wu J, et al. Hypoxia induces myocyte-dependent COX-2 regulation in endothelial cells: Role of VEGF. Am J Physiol Heart Circ Physiol 2003; 285: H2420-H2429.
39. Rechler MM. Insulin-like growth factor binding proteins. Vitam Horm 1993; 47: 1-114.
40. Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3′-untranslated region. J Biol Chem 2000; 275: 11750-11757.
41. Neuss H, Huang X, Hetfeld BK, et al. The ubiquitin- and proteasome-dependent degradation of COX-2 is regulated by the COP9 signalosome and differentially influenced by coxibs. J Mol Med (Berl) 2007; 85: 961-970.
42. Shao J, Sheng H, Inoue H, Morrow JD, DuBois RN. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem 2000; 275: 33951-33956.
43. Rockwell P, Yuan H, Magnusson R, Figueiredo-Pereira ME. Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE(2). Arch Biochem Biophys 2000; 374: 325-333.
44. Muller-Decker K, Berger I, Ackermann K, et al. Cystic duct dilatations and proliferative epithelial lesions in mouse mammary glands upon keratin 5 promoter-driven overexpression of cyclooxygenase-2. Am J Pathol 2005; 166: 575-584.
45. Watanabe T, Satoh H, Togoh M, Taniguchi S, Hashimoto Y, Kurokawa K. Positive and negative regulation of cell proliferation through prostaglandin receptors in NIH-3T3cells. J Cell Physiol 1996; 169: 401-409.
46. Shoji Y, Takahashi M, Kitamura T, et al. Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development. Gut 2004; 53: 1151-1158.
47. Lee JL, Kim A, Kopelovich L, Bickers DR, Athar M. Differential expression of E prostanoid receptors in murine and human non-melanoma skin cancer. J Invest Dermatol 2005; 125: 818-825.
48. Shoji Y, Takahashi M, Takasuka N, et al. Prostaglandin E receptor EP3 deficiency modifies tumor outcome in mouse two-stage skin carcinogenesis. Carcinogenesis 2005; 26: 2116-2122.
49. Schmitz T, Cox LA, Li C, et al. Prostaglandin E2 receptor expression in fetal baboon lung at 0.7 gestation after betamethasone exposure. Pediatr Res 2007; 61: 421-426.
50. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol 2007; 2: 251-275.
51. Pettersson A, Nagy JA, Brown LF, et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest 2000; 80: 99-115.
52. Howe LR, Chang SH, Tolle KC, et al. HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res 2005; 65: 10113-10119.
53. Wang D, DuBois RN. Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proc Natl Acad Sci USA 2004; 101: 415-416.
54. Weller CL, Collington SJ, Hartnell A, et al. Chemotactic action of prostaglandin E2 on mouse mast cells acting via the PGE2 receptor 3. Proc Natl Acad Sci USA 2007; 104: 11712-11717.
55. Maltby S, Khazaie K, McNagny KM. Mast cells in tumor growth: Angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta 2009; 1796: 19-26.
56. Barnes VM, Santarpia P, Richter R, Curtis J, Xu T. Clinical evaluation of the anti-plaque effect of a commercial chewing gum. J Clin Dent 2005; 16: 1-5.
57. Falandry C, Canney PA, Freyer G, Dirix LY. Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Ann Oncol 2009; 20: 615-620.